Journal of Business & Banking
Vol 11, No 2 (2021): November 2021 - April 2022

Does super deduction R&D financial policy in the pandemic Covid-19 give a super reaction?

Cahyani Tunggal Sari (SEKOLAH TINGGI ILMU EKONOMI SEMARANG)
Eni Puji Estuti (Sekolah Tinggi Ilmu Ekonomi Semarang)
Ariyani Indriastuti (Sekolah Tinggi Ilmu Ekonomi Semarang)



Article Info

Publish Date
26 Apr 2022

Abstract

This research was motivated by the announcement of the super deduction R&D finan- cial policy (PMK 153/2020) issued by the Indonesian government during the Covid-19in 2020. This study tried to test and empirically prove either the presence or absence ofabnormal returns on the day around the announcement, before and after the announce-ment optimal portfolio of pharmaceutical and health sector stocks during the observationtime around the announcement of the super deduction R&D financial policy. This isa quantitative research with event study using hypothesis testing from one samplet-test and paired sample t-test. The results showed that there was 1 day of observation,which indicated an abnormal return around the announcement day. Overall, beforeand after being announced based on the results of the paired sample t-test, it did notshow any abnormal returns. The highest optimal portfolio analysis is on stock of Darya Varia Laboratoria company which have a weighting of 40.86% and there are two stocks that are not optimal. This study shows that there is a reaction of market participants to pharmaceutical and health stocks on the announcement even though the reaction is very small. Based on the result, there is a need for information related to research and development activities of pharmaceutical and health companies for investors if they want to improve their stock performance.

Copyrights © 2021